Primary information |
---|
ID | antitb_1454, |
Name | 25809751 |
N-Terminal modification | A24-ESAT6 |
C-Terminal Modification | AYQGVQQKW |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 9 |
Source | L |
Species | Protein derived |
Strain | MTB derived protein ESAT6 |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis Rv |
Sequence | 2104 |
Cytotoxicity | NA |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | NA |
Mechanism of Action | NA |
Target | IL7Rα expression reduced and CD107a expression also decreased among CD8+ T cell after post TB treatment |
Combination Therapy | Drug treatement of TB with antiTB drug found to decrease the frequency of MTB Antigen CD8+ T-cell, so evaluation of these antigenic peptide after TB treatment serve as a valuable marker for the evaluation of TB therapy. |
Other activities | CD8+ T-cell |
PMID | NA |
Year of Publication | NA |
Tertiary Structure (Technique) | Not Predicted), |
Primary information |
---|
ID | antitb_1728, |
Name | US 2002/013197 |
N-Terminal modification | SEQ ID NO 10 |
C-Terminal Modification | AYQGVQQKW |
Chemical Modification | Free |
Linear/Cyclic | Free |
Length | None |
Chirality | Linear |
Nature | 9 |
Source | L |
Species | Protein Derived |
Strain | From the proetins containing mycobacterial CD8 T cell epitopes |
Inhibition Concentration | Mycobacterium tuberculosis |
In Vitro/ In vivo | Mycobacterium tuberculosis |
Inhibition Concentration | In vitro |
Sequence | 2002 |
Cytotoxicity | PBMcs |
In vivo Model | NA |
Lethal Dose | NA |
Immune Responce | β2-microglobulin gene knowckout mice, TAP-1 null mutant mice and HSP-65 immunized mice |
Mechanism of Action | NA |
Target | IFN-γ release increases |
Combination Therapy | By CD8 T cell response |
Other activities | NA |
PMID | None |
Year of Publication | None |
Tertiary Structure (Technique) | Not Predicted), |